Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Feb;7(1):54-57.
doi: 10.5582/irdr.2018.01006.

Intracardiac thrombosis in Behçet's Disease successfully treated with immunosuppressive agents: A case of vascular pathergy phenomenon

Affiliations
Case Reports

Intracardiac thrombosis in Behçet's Disease successfully treated with immunosuppressive agents: A case of vascular pathergy phenomenon

Francisco Galeano-Valle et al. Intractable Rare Dis Res. 2018 Feb.

Abstract

Behçet's Disease (BD) is a rare multi-systemic inflammatory disorder classified as a systemic vasculitis of unknown aetiology. Vascular involvement occurs in approximately 5-51.6% cases, affecting venous and arterial vessels. Cardiac involvement is rare in BD (6%). There have been published approximately 93 cases of BD associated with intracardiac thrombosis, with different treatments and courses. We present a case of a 35-year-old spanish male that, after a percutaneous pharmacomechanical thrombectomy with venous stent placement, developed high fever and extensive venous thrombosis despite anticoagulation including intracardiac thrombosis (ICT) in the right ventricle and pulmonary embolism that leaded to the diagnosis of BD. The patient was successfully treated with immunosuppressants, achieving the complete resolution of ICT. We hypotesize that the endovenous procedure could have acted as a trigger for the posterior acute attack of the disease, representing a 'vascular pathergy phenomenon'. Vascular BD has to be suspected in cases of thrombosis recurrence despite correct anticoagulation, and intense immunosuppressive treatment should be considered.

Keywords: Behçet disease; immunosuppressive agents; intracardiac thrombus; thrombectomy; venous thromboembolism.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A), Positron Emission Tomography - Computed Tomography (PET-CT) shows thrombosis of the stent in the left common iliac vein with two areas of hyper-metabolic activity (white arrows); (B), PET-CT reveals a thrombus in the right ventricle with hyper-metabolic activity (white arrow); (C), Transthoracic echocardiogram (TTE) discloses a rounded moving 30 mm long image (white arrow) sticked on the right ventricle apex with heterogeneous echogenicity, compatible with moving thrombus; (D), TTE performed 2 months later showing total resolution of ICT.

Similar articles

Cited by

References

    1. Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet's disease physiopathology: A contemporary review. Auto Immun Highlights. 2016; 7:4. - PMC - PubMed
    1. Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet's disease: A comprehensive review. J Autoimmun. 2015; 64:137-148. - PMC - PubMed
    1. Seyahi E. Behçet's disease: How to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016; 30:279-295. - PubMed
    1. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet's disease: An update. Curr Opin Rheumatol. 2011; 23:24-31. - PubMed
    1. Fei Y, Li X, Lin S, Song X, Wu O, Zhu Y, Gao X, Zhang W, Zhao Y, Zeng X, Zhang F. Major vascular involvement in Behçet's disease: A retrospective study of 796 patients. Clin Rheumatol. 2013; 32:845-852. - PubMed

Publication types

LinkOut - more resources